WAVE Life Sciences Ltd at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Good. It's time Q&A. And if you have a question, we'll bring a mic over to you, but I can start off. I just want to come back to 007 NAB. I think sort of the -- just given the shortcomings with the GLP-1s, the idea of having in the orthogonal approach that complements the activity there is pretty compelling. But just from a monotherapy standpoint, I'm curious, what's your level of confidence in monotherapy 007 being a obesity reducing agent and the extent to which the current Phase 1 study is kind of -- will inform that expectation?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Yeah. Thank you. In the past, you've talked about work you're doing FTD and ALS. Is that all still in the pipeline?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Just with the -- it's coming back to the 007 candidate and the trial that you're currently running, just in some of the biomarkers that you're assessing, particularly being active in E levels. Can you just talk about sort of the level of knockdown that you think would be -- would translate into a clinical benefit over time. I guess, how early on do you expect to see a change? And maybe there's some commentary around sort of the turnover of activin E that sort of informs the type of knockdown profile you expect to see?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Relative to the GLP-1 studies when you kind of track their development, you guys have the advantage here in this trial to be able to look at durability pretty early on, right? So with that, it seems as though you're set up almost to perhaps move to a pivotal study as potentially the next trial. So I don't want to get too ahead to the SKUs, but maybe just walk us through what you think sort of the additional or the incremental studies might be after this one in the lead up to a potential pivotal trial.

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Maybe just last question on the program. Just in terms of the proof-of-concept readout later this year. I guess, how should we be thinking about